You're welcome... Yes, I have very big hopes for GALT and like the combination of NASH and cancer potential. I agree that GALT would be a good takeover candidate - but sometimes things that seem to be logical never take place in the biotech sector. One risk, if no buyout, might be that the SP will keep slowly bleeding til the readout in 3 years due to a lack of catalysts, on the other hand a market cap of less than 300m for a Phase 3 NASH company with a decent chance of success is ridiculous. Also, if the control group progresses to varices quickly and the GALT-arm shows staggering efficacy, the trial might be halted earlier.

Viking also seems interesting but I didn't do much research on it as of yet. I will probably look into it soon.